RE-BVS – Piemonte Repository

Sfoglia per AUTORE
PROCOPIO G
Collezione ASL Cuneo 2

Items : 9

Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2025 Feb;23(1):102267. doi: 10.1016/j.clgc.2024.102267. Epub 2024 Nov 10.

2025
ASL Cuneo 2
AO Ordine Mauriziano

Puglisi S; Lipari H; Cavo A; Vignani F; Nolè F; Prati G; Morelli F; Spada M; Caffo O; Napoli MD; Atzori F; Malgeri A; Prati V; Sorarù M; Tudini M; Mollica V; Ricotta R; Baldessari C; Fratino L; Merler S; Procopio G; Naglieri E; Masini C; Zucali PA; Galli L; Sbrana A; Chiellino S; De Giorgi U; Maruzzo M; et alii...

Italian Registry on Rare Urological Tumors (Meet-URO-23): The First Analysis on Collecting Duct Carcinoma of the Kidney. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2024 Oct;22(5):102186. doi: 10.1016/j.clgc.2024.102186. Epub 2024 Aug 2.

2024
ASL Cuneo 2

Giudice GC; Maruzzo M; Verzoni E; Procopio G; Bimbatti D; Sepe P; Maines F; Grillone F; Cavo A; Santoni M; Cordua N; Pecoraro G; Prati V; Napoli MD; Ollari E; Caruso G; Simoni N; Campobasso D; Buti S;

Bone health and body composition in prostate cancer: Meet-URO and AIOM consensus about prevention and management strategies. in ESMO open / ESMO Open. 2024 Jul;9(7):103484. doi: 10.1016/j.esmoop.2024.103484. Epub 2024 Jun 19.

2024
ASL Cuneo 2
ASL Asti
AOU Alessandria

De Giorgi U; Santini D; Bertoldo F; Tucci M; Berruti A; Procopio G; Pantano F; Di Maio M; Valsecchi AA; Cursano MC;

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2024 Apr 18;73(6):106. doi: 10.1007/s00262-024-03682-w.

2024
ASL Cuneo 2

Massari F; Santoni M; Takeshita H; Okada Y; Tapia JC; Basso U; Maruzzo M; Scagliarini S; Büttner T; Fornarini G; Myint ZW; Galli L; Souza VC; Pichler R; De Giorgi U; Gandur N; Lam ET; Gilbert D; Popovic L; Grande E; Mammone G; Berardi R; Crabb SJ; Kemp R; Molina-Cerrillo J; Freitas M; Luz M; Iacovelli R; Calabrò F; et alii...

Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: post-hoc analysis of the Meet-URO 15 study. in Frontiers in oncology / Front Oncol. 2024 Feb 12;14:1307635. doi: 10.3389/fonc.2024.1307635. eCollection 2024.

2024
ASL Cuneo 2
AO Ordine Mauriziano

Roviello G; Lipari H; Cavo A; Vignani F; Nolè F; Prati G; Morelli F; Spada M; Caffo O; Di Napoli M; Atzori F; Malgeri A; Prati V; Sorarù M; Tudini M; Mollica V; Ricotta R; Baldessari C; Fratino L; Milella M; Procopio G; Naglieri E; Masini C; Zucali PA; Galli L; Chiellino S; Bimbatti D; De Giorgi U; Rebuzzi SE; et alii...

Pembrolizumab Plus Axitinib for Metastatic Papillary and Chromophobe Renal Cell Carcinoma: NEMESIA (Non Clear MEtaStatic Renal Cell Carcinoma Pembrolizumab Axitinib) Study, a Subgroup Analysis of I-RARE Observational Study (Meet-URO 23a). in International journal of molecular sciences / Int J Mol Sci. 2023 Jan 6;24(2):1096. doi: 10.3390/ijms24021096.

2023
ASL Cuneo 2

Stellato M; Buti S; Maruzzo M; Bersanelli M; Pierantoni F; De Giorgi U; Di Napoli M; Iacovelli R; Vitale MG; Ermacora P; Malgeri A; Maiorano BA; Prati V; Mennitto A; Cavo A; Santoni M; Carella C; Fratino L; Procopio G; Verzoni E; Santini D;

An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study. in ESMO open / ESMO Open. 2023 Aug;8(4):101598. doi: 10.1016/j.esmoop.2023.101598. Epub 2023 Jul 17.

2023
ASL Cuneo 2

Internò V; Massari F; Rudà R; Maiorano BA; Caffo O; Procopio G; Bracarda S; Atzori F; Passarelli A; Bersanelli M; Stellato M; Fornarini G; Galli L; Ortega C; Zanardi E; Incorvaia L; Facchini G; Giron Berrios JR; Ricotta R; Santoni M; Funaioli C; Trerotoli P; Porta C; Rizzo M;

The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study. in Journal of translational medicine / J Transl Med. 2022 Sep 30;20(1):435. doi: 10.1186/s12967-022-03601-6.

2022
ASL Cuneo 2
AO Ordine Mauriziano

Messina M; Caffo O; Di Napoli M; Atzori F; Santini D; Soto Parra HJ; Prati V; Cortellini A; Santoni M; Sorarù M; Mollica V; Panni S; Ricotta R; Pipitone S; Fratino L; Boccardo F; Milella M; Procopio G; Naglieri E; Fantinel E; Zucali PA; Galli L; Chiellino S; Basso U; De Giorgi U; Maruzzo M; Damassi A; Fornarini G; Gandini A; et alii...

The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The ?-Meet-URO analysis. in Frontiers in oncology / Front Oncol. 2022 Sep 23;12:955501. doi: 10.3389/fonc.2022.955501. eCollection 2022.

2022
ASL Cuneo 2
AO Ordine Mauriziano

Nolè F; Prati G; Morelli F; Messina M; Caffo O; Di Napoli M; Atzori F; Soto Parra HJ; Prati V; Cortellini A; Sorarù M; Santoni M; Massari F; Panni S; Ricotta R; Sabbatini R; Fratino L; Boccardo F; Milella M; Procopio G; Carella C; Fantinel E; Zucali PA; Galli L; Pedrazzoli P; De Giorgi U; Maruzzo M; Santini D; Stellato M; et alii...